June 10, 2022
2 mins read

Indian-American doctor leads mRNA vax trial for pancreatic cancer

According to Balachandran, mRNA vaccines could stimulate the immune system to recognise and attack pancreatic cancer cells….reports Asian Lite News

World’s first trial, led by an Indian-American doctor, on a mRNA-based vaccine for pancreatic cancer has shown promise for remission.

The new shot is developed by BioNTech based on the same technology used by the German biotech company along with its US partner Pfizer to develop vaccines against Covid-19.

The groundbreaking trial led by Dr Vinod Balachandran at the Memorial Sloan Kettering Cancer Center (MSK) in New York, showed that half of the patients remained cancer-free 18 months after having their tumours removed and receiving the jabs.

The key to these vaccines appears to be proteins in the pancreatic tumours, called neoantigens, which alert the immune system to keep the cancer at bay, according to MSK. The promising results were also presented at the American Society of Clinical Oncology conference in Chicago.

In 8 of 16 patients studied, the vaccines activated T cells that recognise the patient’s own pancreatic cancers. These patients also showed delayed recurrence of their pancreatic cancers, suggesting the T cells activated by the vaccines may be having the desired effect to keep pancreatic cancers in check.



According to Balachandran, mRNA vaccines could stimulate the immune system to recognise and attack pancreatic cancer cells.

“Unlike some of the other immunotherapies, these mRNA vaccines do appear to have the ability to stimulate immune responses in pancreatic cancer patients,” Balachandran said of the promising preliminary results.

“So we’re very excited about that, and the early results suggest that if you have an immune response, you may have a better outcome.”



Balachandran added the results should be welcome news for other cancer patients too, as pancreatic cancer has been very difficult to treat with traditional chemotherapies and immunotherapies.

The phase-I trial was also heralded as “encouraging” by BioNTech.

“We are committed to taking up this challenge by leveraging our long-standing research in cancer vaccinology and are trying to break new ground in the treatment of such hard-to-treat tumours,” BioNTech co-founder and chief medical officer Prof Ozlem Tureci said.

A similar trial is also currently underway for bowel cancer � and Moderna, another Covid vaccine manufacturer, is also developing mNRA treatments for cancer and autoimmune conditions.

ALSO READ: Meta names Santosh Janardhan as head of engineering

Previous Story

UKHSA issues self-isolation guidance for monkeypox

Next Story

Yoon to attend NATO summit in Spain

Latest from -Top News

Rajasthan Returns to Dubai

This year, the Rajasthan Tourism Board set up their stand at ATM Dubai stage 2025—its first appearance in 15+ years. Under the stewardship of Additional Director Mr. Anand Tripathi, Department of Tourism,

Beijing’s Shadow Over Kashmir Terror

The Pahalgam massacre is not just an act of terror; it is a strategic message. It exposes how Pakistan, increasingly beholden to China, is being used as a tool to undermine India’s

India Calls Out Pakistan’s Double Game

Indian High Commissioner to the UK warned that the current hostilities could cease entirely if Pakistan simply refrains from targeting Indian military installations…reports Asian Lite News Indian High Commissioner to the UK,

Gates to Give 99% Away 

Spread out over time, this will enable the foundation to invest an additional $200 billion (£150.8 billion) in its core focus areas, primarily global health and U.S. education, over the next two
Go toTop

Don't Miss

Lok Sabha passes Demands for Grants and Appropriation Bill

The bill, introduced by Finance Minister Nirmala Sitharaman, was passed

Indian Army chief in B’desh to boost ties

General Naravane’s visit comes in the midst of Swarnim Vijay